OakChart

RxSight Inc

RXSTHealthcare·Medical Devices·USA·Micro·NASD·Nov 11 • 12:38 PM ET

4.90-0.00 (-0.04%)
2026-11-11 18:40 CET
Market cap
205.45 USD m
Revenue, TTM
121.83 USD m
Net income, TTM
-53.36 USD m
Free cash flow, TTM
18.64 USD m
EPS diluted, TTM
-1.29
P/E
-
Compare

Price

RXST against its 20, 50 and 200-day averages
2050200beatmiss
4.006.008.002.4M4.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RXSTclose 4.9020-day 4.8350-day 5.09200-day 6.174.9052w low

63.0% under the 52-week high of 13.22 on 11 Dec 2025. 52-week low 4.11 on 4 Nov 2026. Last 15 sessions, 32.5% high to low

Profile

RXST
52-week range, 9% of the way up
4.1113.22

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

IndexRUT
Employees461
IPOJul 30, 2021
Beta1.19
ATR, 14d0.34
Rel volume0.36
Short float9.34%
Insider own7.24%
Inst own100.31%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap205.36M
Enterprise Value-39.00M
Income-53.36M
Sales121.83M
Book/sh6.08
Cash/sh6.07
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees461
IPOJul 30, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S1.69
P/B0.81
P/C0.81
P/FCF11.02
EV/EBITDA-
EV/Sales-0.32
Quick Ratio3.67
Current Ratio4.20
Debt/Eq0.04
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.29
EPS next Y-1.24
EPS next Q0.23
EPS this Y15.30%
EPS next Y-53.81%
EPS next 5Y4.11%
EPS past 3/5Y26.63% -
Sales past 3/5Y40.00% 55.74%
EPS Y/Y TTM-46.60%
Sales Y/Y TTM-14.26%
EPS Q/Q-62.35%
Sales Q/Q-18.97%
EarningsNov 03 AMC
EPS/Sales Surpr.-27.20% -9.59%

Ownership

Insider Own7.24%
Insider Trans-0.56%
Inst Own100.31%
Inst Trans-7.90%
ROA-16.44%
ROE-20.10%
ROIC-20.26%
Gross Margin76.13%
Oper. Margin-50.44%
Profit Margin-43.80%
SMA201.49%
SMA50-3.78%
SMA200-20.60%
Trades-

Technical

Shs Outstand41.93M
Shs Float38.89M
Short Float9.34%
Short Ratio4.34
Short Interest3.63M
52W High13.22 -62.95%
52W Low4.11 19.17%
Volatility14.18% 7.14%
ATR (14)0.34
RSI (14)50.39
Beta1.19
Rel Volume0.36
Avg Volume836.38K
Volume151,948

Performance

Perf Week-1.85%
Perf Month8.12%
Perf Quarter-30.13%
Perf Half Y-11.75%
Perf YTD-53.00%
Perf Year-52.12%
Perf 3Y-80.63%
Perf 5Y-61.22%
Perf 10Y-
Recom3.10
Target Price6.11
Prev Close4.90
Price4.90
Change %-0.04%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jan 30, 2026InitiatedWWilliam BlairMkt Perform
Jul 15, 2025DowngradeMMorgan StanleyOverweight → Equal-Weight$9+83.8%
Jul 10, 2025DowngradeJJefferiesBuy → Hold$9+83.8%
Jul 09, 2025DowngradeWWells FargoOverweight → Equal Weight$9+83.8%
Jul 09, 2025DowngradeOOppenheimerOutperform → Perform
Jul 09, 2025DowngradeBBTIG ResearchBuy → Neutral
May 19, 2025UpgradeWWells FargoEqual Weight → Overweight$25+410.4%
Apr 15, 2025InitiatedPPiper SandlerNeutral$18+267.5%
Apr 09, 2025DowngradeUUBSBuy → Neutral$16+226.7%
Apr 04, 2025DowngradeJJP MorganOverweight → Underweight$40 → $17+247.1%

Peers

Mkt cap
TickerCompanyMkt cap
LNSRLENSAR Inc54.43M
ALCAlcon Inc34.63B
STAAStaar Surgical Co1.29B
BLCOBausch + Lomb Corp7.60B
SGHTSight Sciences Inc600.80M
GKOSGlaukos Corp14.49B
COOCooper Companies Inc11.90B
HROWHarrow Inc1.09B
INMDInmode Ltd777.99M
EYPTEyePoint Inc31.54M

Insider trading

11 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Weinberg EricSee remarksSep 15 '26Option Exercise4.3435,168152,629235,516Sep 16 04:25 PM
Kurtz Ronald M MDOfficerSep 02 '26Proposed Sale6.965,10035,496Sep 02 09:45 PM
Wilterding MarkOfficerSep 02 '26Proposed Sale6.967,76554,044Sep 02 09:43 PM
Goldshleger IlyaOfficerSep 02 '26Proposed Sale6.962,04114,205Sep 02 09:40 PM
Weinberg EricOfficerSep 02 '26Proposed Sale6.962,04114,205Sep 02 09:38 PM
Kurtz Ronald M MDChief Medical OfficerSep 02 '26Sale6.965,10035,49671,775Sep 02 09:35 PM
Wilterding MarkChief Financial OfficerSep 02 '26Sale6.967,76554,04425,049Sep 02 09:35 PM
Goldshleger IlyaChief Operating OfficerSep 02 '26Sale6.962,04114,20581,509Sep 02 09:34 PM
Weinberg EricSee remarksSep 02 '26Sale6.962,04114,205200,348Sep 02 09:33 PM
RAYMOND W COHENFormer DirectorAug 18 '26Proposed Sale6.3711,89075,749Aug 18 05:45 PM
Goldshleger IlyaChief Operating OfficerApr 17 '26Option Exercise4.1312,48951,58078,180Apr 20 04:19 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 206
  • RxSight Edges Past EPS Estimates, But A Revenue Miss And A Fourth Straight Unit Decline Push The Turnaround Into 2027 (Earnings Whispers) +8.71%
  • RxSight, Inc. Reports Third Quarter 2026 Results (GlobeNewswire)
  • RxSight Heads Into Third Quarter With Wall Street Bracing For Shrinking Sales And Wider Losses (Earnings Whispers)
  • RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules (GlobeNewswire)
  • RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3 (GlobeNewswire)
  • Loading…
  • RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation (GlobeNewswire)
  • RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference (GlobeNewswire)
  • Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside (GuruFocus.com)
  • RxSight Inc (RXST) (Q2 2026) Earnings Call Highlights: Strategic Pivot Amid Revenue Decline and ... (GuruFocus.com)
  • RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook (GlobeNewswire)
  • RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules (GlobeNewswire)
  • RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer (GlobeNewswire) +6.71% +6.10%
  • RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.390-0.307-0.39024.5927.1910
2026Q22026-08-05-0.290-0.329-0.29233.7432.5510
2026Q12026-05-06-0.380-0.299-0.38530.8929.759
2025Q42026-02-25-0.220-0.335-0.22232.6130.1710
2025Q32025-11-05-0.240-0.376-0.24030.3025.289
2025Q22025-08-07-0.290-0.254-0.28933.6434.799
2025Q12025-05-07-0.200-0.217-0.20237.9038.0810
2024Q42025-02-25-0.150-0.166-0.14740.2140.319
2024Q32024-11-07-0.160-0.246-0.15935.3135.068
2024Q22024-08-05-0.160-0.223-0.15834.8932.337
2024Q12024-05-06-0.250-0.294-0.24729.5127.567
2023Q42024-02-28-0.260-0.376-0.25528.5828.256
2023Q32023-11-09-0.350-0.433-0.34822.2020.556
2023Q22023-08-07-0.400-0.471-0.40020.8119.236
2023Q12023-05-09-0.420-0.530-0.41817.4916.286
2022Q42023-03-06-0.560-0.749-0.55816.1015.855

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-3.220-2.663-1.77922.5922.04
2022FY-2.410-2.608-2.41349.0048.76
2023FY-1.410-1.531-1.41189.0888.44
2024FY-0.710-0.723-0.706139.93140.03
2025FY-0.950-1.054-0.950134.48131.62
2026FY--0.805--147.42
2027FY--1.238--120.1
2028FY--0.838--138.12

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-04105457.9253.8561.05
2026Q4S2026-11-03100155.2029.0061.05
2026Q4S2026-10-21100155.2029.0061.05
2026Q4S2026-10-20101155.2029.0061.05
2026Q4S2026-10-09108255.2029.0061.05
2026Q4S2026-09-21108255.2029.0061.05
2026Q4S2026-08-31109155.4029.0061.10
2026Q4S2026-08-19109155.4029.0061.10
2026Q4S2026-08-07109155.4029.0061.10
2026Q4S2026-08-06108153.0429.0061.10
2026Q4S2026-07-27103039.2433.9047.40
2026Q4S2026-07-2193038.3533.9047.40
2026Q4S2026-07-1093438.3533.9047.40
2026Q4S2026-07-0793438.3633.9047.40

Estimate history

EPS, annual0.9460.122-1.779-2.413-1.411-0.706-0.953-1.2874
Period2019202020212022202320242025TTM
EPS, quarterly-0.159-0.147-0.202-0.289-0.24-0.222-0.385-0.292-0.389
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual2.24114.67822.59349.00589.077139.927134.479121.83
Period2019202020212022202320242025TTM
Sales, quarterly35.31440.21437.89533.63730.3432.60830.89333.74124.586
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual27.62327.62327.36728.26836.1440.42841.24241.927
Period2019202020212022202320242025MRQ
Shares, quarterly40.25440.42840.58940.91341.08241.24241.38441.58541.927
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue121.83134.48139.9389.0849.0122.5914.682.24
Cost of Goods Sold Incl. D&A29.0831.4740.9835.3127.6818.0812.974.06
Gross Profit92.75103.0198.9453.7721.334.521.71-1.82
Selling, General and Administrative Excl. Other154.20151.20135.80103.8584.6557.3037.1144.77
Research and Development36.8338.5534.3729.0525.9824.5021.9329.57
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-61.45-48.19-36.86-50.09-63.32-52.79-35.41-46.59
Interest Expense0.010.020.023.314.953.680.510.03
Unusual Expense0.000.000.001.770.00-2.72-63.01-169.23
Net Income Before Taxes-53.23-38.88-27.41-48.59-66.75-48.6827.63126.24
Income Taxes0.130.070.050.020.010.010.060.02
Consolidated Net Income-53.36-38.94-27.45-48.61-66.76-48.6927.57108.25
Net Income From Continuing Operations-53.36-38.94-27.45-48.61-66.76-48.6927.57108.25
Net Income-53.36-38.94-27.45-48.61-66.76-48.693.3726.13
EPS (Recurring)-1.28-0.95-0.71-1.37-2.41-1.85-1.47-3.34
EPS (Basic, Before Extraordinaries)-1.29-0.95-0.71-1.41-2.41-1.780.120.95
EPS (Diluted)-1.29-0.95-0.71-1.41-2.41-1.780.120.95
EBITDA-57.84-44.92-33.23-45.84-59.30-48.80-31.39-42.66
Non-Operating Income (Expense)8.249.339.476.571.525.070.543.63
Other After Tax Adjustments0.000.000.000.000.000.000.00-17.97
Stock Option Compensation Expense24.3824.9719.4612.449.005.53--
Price To Sales Ratio1.683.179.5515.607.1513.63--
Gross Margin76.1376.6070.7160.3643.5219.9911.62-81.17
Operating Margin-50.44-35.84-26.34-56.23-129.21-233.64-241.21-2,079.03
Net Margin-43.80-28.96-19.62-54.57-136.22-215.5022.931,165.86
Shares Outstanding41.9341.2440.4336.1428.2727.3727.6227.62
Market Capitalization205.45205.451,385.671,445.94351.23307.73289.13-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue24.5933.7430.8932.6130.3433.6437.9040.21
Cost of Goods Sold Incl. D&A6.497.867.397.346.118.459.5711.43
Gross Profit18.1025.8923.5025.2624.2325.1928.3328.79
Selling, General and Administrative Excl. Other36.6239.6641.3336.6036.4139.1939.0037.42
Research and Development9.219.249.478.909.0610.2210.379.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-18.52-13.77-17.83-11.34-12.18-14.00-10.67-8.63
Interest Expense0.000.000.000.010.000.010.010.01
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-16.20-12.01-15.88-9.15-9.81-11.75-8.17-5.93
Income Taxes0.030.090.010.010.010.030.020.01
Consolidated Net Income-16.22-12.10-15.88-9.15-9.82-11.79-8.19-5.94
Net Income From Continuing Operations-16.22-12.10-15.88-9.15-9.82-11.79-8.19-5.94
Net Income-16.22-12.10-15.88-9.15-9.82-11.79-8.19-5.94
EPS (Recurring)-0.39-0.29-0.38-0.22-0.24-0.29-0.20-0.15
EPS (Basic, Before Extraordinaries)-0.39-0.29-0.38-0.22-0.24-0.29-0.20-0.15
EPS (Diluted)-0.39-0.29-0.38-0.22-0.24-0.29-0.20-0.15
EBITDA-17.59-12.77-17.00-10.49-11.32-13.22-9.89-8.11
Non-Operating Income (Expense)2.331.761.952.192.382.252.512.71
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.035.906.286.186.416.755.645.75
Price To Sales Ratio1.681.572.003.192.593.606.909.92
Gross Margin73.6276.7276.0677.4779.8574.8974.7671.59
Operating Margin-75.32-40.81-57.71-34.77-40.14-41.63-28.17-21.46
Net Margin-65.99-35.85-51.42-28.07-32.35-35.04-21.61-14.77
Shares Outstanding41.9341.5941.3841.2441.0840.9140.5940.43
Market Capitalization205.45199.53254.20428.44367.83528.281,022.391,385.67

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments228.13237.22127.18105.80159.3368.9780.67
Short Term Receivables23.3830.0520.2810.964.862.870.79
Inventories31.5622.0117.4214.848.038.297.22
Other Current Assets4.394.543.522.964.071.371.52
Total Current Assets287.46293.82168.41134.56176.2981.5090.20
Net Property, Plant & Equipment23.0223.6313.2914.0815.5018.6119.25
Total Investments and Advances0.750.750.710.760.810.460.87
Deferred Tax Assets2.532.86-----
Other Assets0.590.360.150.770.110.110.11
Total Assets314.35321.42182.55150.16192.72100.68110.43
Short Term Debt Incl. Current Port. of LT Debt1.160.971.801.971.531.270.99
Accounts Payable5.304.543.862.601.691.132.20
Other Current Liabilities19.8020.3615.2412.677.869.195.27
Total Current Liabilities26.2525.8820.9017.2411.0811.608.46
Long Term Debt9.8811.321.2143.0243.4029.484.53
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities2.532.86-----
Other Liabilities0.000.130.070.000.003.8374.48
Total Liabilities38.6640.1822.1960.2654.4844.9187.46
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00353.30327.58
Common Equity275.68281.24160.3689.90138.24-297.53-304.61
Total Shareholders Equity275.68281.24160.3689.90138.2455.7722.97
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity275.68281.24160.3689.90138.2455.7722.97
Total Liabilities & Stockholders Equity314.35321.42182.55150.16192.72100.68110.43
Book Value Per Share6.686.964.443.185.05-10.77-11.03
Tangible Book Value Per Share6.686.964.443.185.05-10.77-11.03
Full-Time Employees461498374292221--
Price to Book Ratio0.814.998.953.662.231.72-
Return on Assets-12.25-10.90-29.22-38.94-33.1926.12-
Return on Equity-13.99-12.43-38.85-58.52-50.1970.04-
Return on Invested Capital-13.64-9.38-30.08-50.22-26.8032.35393.69
Quick Ratio9.7510.507.226.9515.196.319.81
Current Ratio10.9511.368.067.8115.927.0310.67

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-53.36-38.94-27.45-48.61-66.76-48.6927.57126.22
Depreciation3.613.273.624.244.023.994.013.93
Other Funds (Non Cash)27.4525.0616.109.6111.152.67-58.94-166.80
Funds from Operations-22.30-10.62-7.74-34.76-51.58-42.03-27.36-36.65
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital45.97-4.89-9.21-9.07-7.41-2.68-7.85-3.97
Cash from Operating Activities23.67-15.51-16.95-43.83-58.99-44.71-35.20-40.62
Capital Expenditures-5.03-3.83-5.44-4.81-2.39-1.94-2.54-4.09
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.60
Purchase or Sale of Investments16.8620.72-93.87-17.3242.34-79.9718.13-2.39
Purchase of Investments-405.14-239.28-336.87-272.31-212.66-159.97-97.87-132.39
Sale Or Maturity of Investments422.00260.00243.00255.00255.0080.00116.00130.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities11.8316.89-99.31-22.1339.95-81.9115.59-5.87
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock2.103.95128.15105.337.24121.931.011.59
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock2.103.95128.15105.337.24121.931.011.59
Proceedsfrom Stock Options2.103.95128.15105.337.24119.581.011.59
Issuance or Reduction of Debt, Net-0.01-0.03-0.06-40.15-0.1214.8424.17-0.18
Change in Long Term Debt-0.01-0.03-0.06-40.15-0.1214.8424.17-0.18
Issuance of Long Term Debt0.000.000.0020.000.0014.8724.310.00
Reduction of Long Term Debt-0.01-0.03-0.06-60.15-0.12-0.03-0.14-0.18
Net Financing Active Other Cash Flow-0.50-2.06-4.77-1.42-0.640.570.05-0.08
Other Financing Activities Uses-0.50-2.06-4.77-1.42-0.640.000.00-0.08
Cash from Financing Activities1.581.86123.3263.766.48137.3425.241.33
Exchange Rate Effect-0.000.00-0.010.01-0.01-0.010.000.01
Net Change in Cash37.093.247.05-2.19-12.5810.725.62-45.15
Free Cash Flow18.64-19.34-22.39-48.64-61.39-46.65-37.74-44.70
Preferred Dividends (Cash Flow)-0.000.000.000.000.00--
Price to Free Cash Flow10.96-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments254.68208.80217.88228.13227.52227.49
Short Term Receivables17.0078.5222.4423.3824.1528.06
Inventories39.5937.1234.8731.5628.9525.06
Other Current Assets3.532.964.034.393.263.26
Total Current Assets314.80327.40279.23287.46283.88283.87
Net Property, Plant & Equipment23.8923.5322.9923.0223.3723.84
Total Investments and Advances0.750.750.750.750.750.75
Deferred Tax Assets---2.53--
Other Assets0.971.021.030.590.540.54
Total Assets340.42352.70303.99314.35308.53309.01
Short Term Debt Incl. Current Port. of LT Debt1.841.661.501.161.291.10
Accounts Payable3.426.347.125.303.383.35
Other Current Liabilities69.6972.4418.7519.8017.6215.93
Total Current Liabilities74.9580.4427.3826.2522.2920.38
Long Term Debt8.488.929.329.8810.2710.61
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---2.53--
Other Liabilities2.080.000.000.000.000.00
Total Liabilities85.5189.3636.7038.6632.5631.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity254.91263.34267.30275.68275.97278.01
Total Shareholders Equity254.91263.34267.30275.68275.97278.01
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity254.91263.34267.30275.68275.97278.01
Total Liabilities & Stockholders Equity340.42352.70303.99314.35308.53309.01
Book Value Per Share6.086.336.466.686.726.80
Tangible Book Value Per Share6.086.336.466.686.726.80
Full-Time Employees---461--
Price to Book Ratio0.810.750.921.551.321.89
Return on Assets-16.44-14.19-15.12-12.25-11.54-10.50
Return on Equity-20.10-17.35-17.06-13.99-12.92-11.66
Return on Invested Capital-6.16-4.44-5.74-3.20-3.43-4.08
Quick Ratio3.673.618.939.7511.4412.70
Current Ratio4.204.0710.2010.9512.7413.93

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-16.23-12.10-15.88-9.15-9.82-11.79
Depreciation0.931.000.830.850.850.78
Other Funds (Non Cash)7.667.046.156.606.037.65
Funds from Operations-7.64-4.06-8.90-1.70-2.93-3.36
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital52.85-5.47-1.990.581.75-1.01
Cash from Operating Activities45.22-9.54-10.89-1.12-1.19-4.38
Capital Expenditures-1.17-1.96-0.76-1.14-0.58-1.54
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments9.126.619.61-8.48-8.4216.19
Purchase of Investments-112.88-93.39-100.39-98.48-68.42-33.81
Sale Or Maturity of Investments122.00100.00110.0090.0060.0050.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities7.954.658.85-9.61-9.0014.65
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.230.670.141.060.132.07
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.230.670.141.060.132.07
Proceedsfrom Stock Options0.230.670.141.060.132.07
Issuance or Reduction of Debt, Net-0.01-0.01-0.010.01-0.02-0.00
Change in Long Term Debt-0.01-0.01-0.010.01-0.02-0.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.01-0.01-0.010.01-0.02-0.00
Net Financing Active Other Cash Flow-0.030.00-0.47-0.00-0.640.00
Other Financing Activities Uses-0.030.00-0.47-0.00-0.640.00
Cash from Financing Activities0.200.66-0.341.06-0.532.06
Exchange Rate Effect0.010.000.00-0.01-0.000.01
Net Change in Cash53.37-4.22-2.38-9.68-10.7212.36
Free Cash Flow44.04-11.49-11.65-2.25-1.77-5.91
Price to Free Cash Flow10.96-----

Revenue breakdown

Light Adjustable Lenses and Related Capital Equipment2024: 96.50M 2025: 108.06M
Light Delivery Devices2024: 39.70M 2025: 20.67M
Service Warranty Service Contracts And Accessories2024: 3.73M 2025: 5.75M
United States2024: 139.93M 2025: 134.48M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.34%3.6M38.9M780.14K
2026-10-1510.68%4.1M38.6M857.46K
2026-09-3010.60%4.1M38.6M972.24K
2026-09-1510.31%4.0M38.6M1.09M
2026-08-3110.04%3.9M38.6M1.15M
2026-08-1411.03%4.3M38.6M1.13M
2026-07-3110.50%4.1M38.6M1.11M
2026-07-159.99%3.8M38.5M1.03M
2026-06-3014.34%5.5M38.5M949.69K
2026-06-1511.20%4.2M37.3M787.59K
2026-05-2910.75%4.2M38.8M724.19K
2026-05-1512.51%4.9M38.8M755.30K
2026-04-3014.39%5.6M38.7M808.77K
2026-04-1514.43%5.6M38.6M904.17K
2026-03-3113.11%5.1M38.6M965.73K
2026-03-1313.12%5.1M38.6M944.36K
2026-02-2714.32%5.5M38.6M964.05K
2026-02-1313.92%5.4M38.5M952.69K
2026-01-3010.74%4.1M38.6M918.71K
2026-01-1512.39%4.8M38.6M814.29K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.054.900.0028.1640.000.000.878-0.0700.002
call5.000.100.750.252.59035.000.000.557-0.0420.003
call7.500.000.750.004.6910.000.000.416-0.0780.003
call10.000.000.750.005.8350.000.000.374-0.0940.003
put2.500.000.750.008.0490.000.00-0.122-0.0690.002
put5.000.000.750.602.26122.000.00-0.445-0.0410.003
put7.500.104.900.009.8840.000.00-0.584-0.0770.003
put10.002.607.500.0011.3840.000.00-0.626-0.0930.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-03S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-11-02SCHEDULE 13G/ASEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-27SCHEDULE 13G/ASEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-05SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-05SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-05SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-05SEC
2026-09-08SC TO-I/ASEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-25SC TO-I/ASEC
2026-08-19SCHEDULE 13GSEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-10SC TO-IIssuer tender offer statementSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-04SCHEDULE 13G/ASEC
2026-07-244Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-243Initial statement of beneficial ownership of securities2026-07-20SEC
2026-07-23S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900117.95K4
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.13.99%
MILLENNIUM MANAGEMENT LLC7.32%
No Street GP LP4.96%
NOMURA HOLDINGS INC4.83%
D. E. Shaw & Co., Inc.4.80%
VANGUARD CAPITAL MANAGEMENT LLC4.05%
AQR CAPITAL MANAGEMENT LLC3.71%
ACADIAN ASSET MANAGEMENT LLC3.48%
FEDERATED HERMES, INC.2.90%
TWO SIGMA INVESTMENTS, LP2.77%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.96%
iShares Russell 2000 ETF2.48%
BlackRock Advantage Small Cap Core Fund2.48%
Federated Hermes MDT Small Cap Core Fund1.56%
Fidelity Small Cap Index Fund1.05%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
iShares Russell 2000 Value ETF0.81%
Bridge Builder Small/Mid Cap Growth Fund0.73%
VANGUARD RUSSELL 2000 INDEX FUND0.55%
NORTH SQUARE DYNAMIC SMALL CAP FUND0.53%

OakChart. RXST. Cached 15 minutes.